Compare BLSH & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BLSH | ICUI |
|---|---|---|
| Founded | 2020 | 1984 |
| Country | Cayman Islands | United States |
| Employees | 414 | N/A |
| Industry | Finance: Consumer Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.6B |
| IPO Year | N/A | 1995 |
| Metric | BLSH | ICUI |
|---|---|---|
| Price | $22.47 | $157.75 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 3 |
| Target Price | $51.91 | ★ $169.00 |
| AVG Volume (30 Days) | ★ 1.6M | 278.8K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.62 |
| EPS | N/A | ★ 1.20 |
| Revenue | N/A | ★ $2,231,262,000.00 |
| Revenue This Year | $64.30 | N/A |
| Revenue Next Year | $17.90 | $4.46 |
| P/E Ratio | ★ N/A | $135.15 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $21.76 | $107.02 |
| 52 Week High | $74.98 | $162.82 |
| Indicator | BLSH | ICUI |
|---|---|---|
| Relative Strength Index (RSI) | 37.59 | 59.80 |
| Support Level | $21.76 | $146.59 |
| Resistance Level | $27.22 | $160.78 |
| Average True Range (ATR) | 1.52 | 5.34 |
| MACD | 0.23 | 0.17 |
| Stochastic Oscillator | 3.06 | 73.12 |
Bullish is an institutionally focused global digital asset platform focused on providing market infrastructure and information services. Its objective is to provide mission critical products and services that are designed to help institutions grow their businesses, empower individual investors, and drive the adoption of stablecoins, digital assets, and blockchain technology. It expanded its product offering to provide trusted insights, authoritative news, data, indices and transparent analysis to the digital assets industry while facilitating partnerships, investment opportunities, and community engagement through its flagship Consensus conference.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.